Elizabeth Ayebare Ombeva
ID: UNCST-2020-R003666
|
An education package to improve health worker communication with women and families after stillbirth or neonatal death: A feasibility study
REFNo: HS1102ES
1. To pilot an education package and associated resources, including train the trainer/training manuals and audio-visual aids to improve health worker communication in Malawi, Uganda, Zambia and Zimbabwe.
2. For feasibility
a. Explore the acceptability and implementation of the package with facility staff receiving training, trainers and service managers across settings.
b. Explore the acceptability and implementation of the package with undergraduate midwifery students receiving training.
c. Assess uptake and attendance/completion of the package.
d. Explore impacts of the research and education package on practice and clinical services.
3. To prepare for a full-scale evaluation:
a. Define the most appropriate primary and secondary outcomes to assess the effect of the educational package on health workers’ communication and parents’ experiences.
b. Assess the acceptability and burden of data collection for participants.
c. Use data to optimise the design and estimate the sample size for a full-scale trial.
d. Exploration of key resources associated with implementing the educational package will be completed to provide an economic understanding of the intervention and its potential impact.
e. To utilise existing and develop additional networks to identify potential sites for a full-scale trial.
4. To combine the feasibility, acceptability and uptake data to develop a full trial protocol by the end of the study.
|
Uganda |
2021-04-21 |
2024-04-21 |
Medical and Health Sciences |
|
Non-degree Award |
|
Nixon Niyonzima
ID: UNCST-2020-R014577
|
SARS-CoV-2 seroconversion: a sero prevalence study among cancer patients and health workers at the Uganda Cancer Institute
REFNo: HS1240ES
3. To describe the temporal trends in the anti- SARS-CoV-2 antibody sero-prevalence among cancer patients at the Uganda Cancer Institute,2. To describe the clinical and demographic characteristics associated with history of exposure to SARS-CoV-2 and severity of COVID-19 disease in cancer patients. ,1. To determine SARS-CoV-2 antibody sero-prevalence in cancer patients attending care at the Uganda Cancer Institute,
|
Uganda |
2021-04-21 |
2024-04-21 |
Medical and Health Sciences |
|
Non-degree Award |
|
Conrad Muzoora Kihembe
ID: UNCST-2019-R001432
|
A randomized clinical TriaL of early empiric Anti-Mycobacterium tuberculosis therapy for Sepsis in sub-Saharan Africa (ATLAS trial)
REFNo: HS1272ES
The primary hypothesis of this clinical trial protocol is that immediate and sepsis specific dose of anti-TB therapy will result in improved 28-day mortality for study participants admitted to hospital with HIV and sepsis in Tanzania and Uganda compared to standard care alone.
The primary objective is:
1) To conduct a randomized 2x2 factorial clinical trial of 1) immediate initiation of empiric anti-TB therapy plus standard care vs diagnosis dependent anti-TB therapy plus standard care alone and 2) sepsis-specific anti-TB therapy plus standard care vs conventional WHO weight-based anti-TB therapy plus standard care for patients presenting with sepsis to two hospitals in Uganda and Tanzania.
1a) To determine if empiric immediate initiation of anti-TB therapy plus standard care improves 28 day mortality compared to diagnosis dependent anti-TB therapy plus standard care.
1b) To determine if sepsis-specific dose anti-TB therapy plus standard care improves 28 day mortality compared to conventional WHO weight-based anti-TB therapy plus standard care.
The secondary objectives include:
1) To determine if empiric immediate initiation of anti-TB therapy plus standard care improves in-hospital mortality compared to diagnosis dependent anti-TB therapy plus standard care
2) To determine if sepsis-specific dose anti-TB therapy plus standard care improves in hospital mortality compared to conventional WHO weight-based anti-TB therapy plus standard care.
3) To determine if empiric immediate initiation of anti-TB therapy plus standard care improves 6 month mortality compared to diagnosis dependent anti-TB therapy plus standard care
4) To determine if sepsis-specific dose anti-TB therapy plus standard care improves 6 month mortality compared to conventional WHO weight-based anti-TB therapy plus standard care.
5) To determine the safety of increased dose anti-TB therapy for patients with sepsis
6) To determine if early achievement of target serum drug concentrations of isoniazid and rifampin, measured at day-2 of TB treatment, associates with more rapid clinical improvement among patients with confirmed TB.
|
Uganda |
2021-04-21 |
2024-04-21 |
Medical and Health Sciences |
|
Non-degree Award |
|
Harriet Mayanja-Kizza
ID: UNCST-2021-R013074
|
A Survey Assessing Male Reproduction During or After Treatment Containing Pretomanid
REFNo: HS1340ES
To evaluate the paternity status in male participants who have received a pretomanid containing regimen in one of the following TB Alliance clinical trials: STAND, Nix-TB, SimpliciTB or ZeNix.
|
Uganda |
2021-04-21 |
2024-04-21 |
Medical and Health Sciences |
|
Non-degree Award |
|
Freddy Kitutu Eric
ID: UNCST-2020-R014751
|
Using community influencer groups to address COVID-19 misinformation and vaccine hesitancy in Buikwe, Uganda
REFNo: HS1140ES
The evaluate the effect of community influencer groups on COVID-19 misinformation and potential COVID-19 vaccine hesitancy.,To form and empower community influencer groups against COVID-19 misinformation and potential COVID-19 vaccine hesitancy ,To explore the effect of COVID-19 misinformation on potential hesitancy towards a future COVID-19 vaccine,To determine the prevalence of potential hesitancy to a future COVID-19 vaccine in Buikwe,To determine the prevalence of COVID-19 misinformation in Buikwe,
|
Uganda |
2021-04-15 |
2024-04-15 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|